Showing 9641-9650 of 20328 results for "".
- EYLEA HD Label Update Enables Extended Dosing Intervalshttps://reachmd.com/news/eylea-hd-label-update-enables-extended-dosing-intervals/2486502/Key Takeaways: The press release reports that the FDA updated the EYLEA HD label to permit consideration of individualized dosing intervals up to ~20 weeks in selected patients after sustained response in wAMD and DME. The announcement cites 96-week da
- Pentanucleotide Instability Observed in MSI-H Colorectal Cancerhttps://reachmd.com/news/pentanucleotide-instability-observed-in-msi-h-colorectal-cancer/2486506/Key Takeaways: The authors report higher rates of combined and locus-specific Penta-C/Penta-D discordance in MSI-H versus MSS colorectal cancers. Penta-D demonstrated greater instability than Penta-C in MSI-H tumors, highlighting locus-specific variabi
- Systematic Review Examines Vaginal Laser and Radiofrequency for Stress Urinary Incontinencehttps://reachmd.com/news/systematic-review-examines-vaginal-laser-and-radiofrequency-for-stress-urinary-incontinence/2486518/In a systematic review and meta-analysis published in International Urogynecology Journal, investigators reported that energy-based devices may offer modest short-term symptom improvement for women with stress urinary incontinence compared with sham treatment. David Lukanović, Gee
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://reachmd.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- TYK2-JAK1 Inhibitor Treatment Promising for Individuals with Refractory Dermatomyositishttps://reachmd.com/news/tyk2-jak1-inhibitor-treatment-promising-for-individuals-with-refractory-dermatomyositis/2486481/Results from the Phase 3 VALOR trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting revealed that individuals with re
- AI-based CCTA plaque quantification vs IVUS: INVICTUS Registry abstracthttps://reachmd.com/news/ai-based-ccta-plaque-quantification-vs-ivus-invictus-registry-abstract/2486488/The INVICTUS Registry abstract describes an automated artificial intelligence workflow for coronary CT angiography plaque quantification being assessed
- AAD 2026: New Study Highlights Dual-Action Antioxidant Serum for UV-Induced Skin Protectionhttps://reachmd.com/news/aad-2026-new-study-highlights-dual-action-antioxidant-serum-for-uv-induced-skin-protection/2486463/New research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlights the potential of a multifunctional antioxidant serum, AOX2.0, to protect human skin from ultraviolet (UV)-induced damage while supporting epidermal recovery. The study examined how oxidative stress
- Combination Therapy Improves Outcomes in Psoriatic Arthritis With Obesityhttps://reachmd.com/news/combination-therapy-improves-outcomes-in-psoriatic-arthritis-with-obesity/2486455/Combination therapy with ixekizumab and tirzepatide demonstrated superior disease control compared with ixekizumab alone in adults with psoriatic arthritis (PsA) and overweight or obesity, according to Phase 3b TOGETHER-PsA results presented by Joseph F. Merola, MD, MMSc, at the American Academy
- IL-15 Blockade Plus Phototherapy Shows Promise in Vitiligohttps://reachmd.com/news/il-15-blockade-plus-phototherapy-shows-promise-in-vitiligo/2486454/Targeting IL-15 with ordesekimab in combination with narrowband ultraviolet B (nbUVB) phototherapy led to greater repigmentation in patients with non-segmental vitiligo, according to results from a randomized, placebo-controlled trial presented by Brett King, MD, PhD, at the American Academy of D
- Dersimelagon Improves Sunlight Tolerance in EPP and XLPhttps://reachmd.com/news/dersimelagon-improves-sunlight-tolerance-in-epp-and-xlp/2486452/Dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist, significantly improved sunlight tolerance in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), according to Phase 3 INSPIRE trial results presented by Amy Dickey Yeung, MD, at the American Academy of